Longevity pharma and RAIN treasury Enlivex secures $21 million debt financing
Enlivex, a Nasdaq-listed longevity company doubling as a RAIN digital asset treasury, said Tuesday it has secured $21 million in debt financing.
The company struck the financing deal with New York-based The Lind Partners, an institutional fund manager, according to a statement.
"We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, allowing us to continue the execution of our operating plan, as well as to acquire approximately three billion additional RAIN tokens," Enlivex Executive Chairman Shai Novik said.
In November, Enlivex said it planned to raise $212 million through a private investment in public equity (PIPE) to launch a RAIN token digital asset treasury. The company said it would become the first DAT built around a prediction-markets token.
Rain is self-described as "a fully decentralized prediction markets protocol" on the Arbitrum network. It provides users with the ability to create markets and trade custom options on any event in any language using AI-resolved outcomes and a buyback-and-burn mechanism tied to the RAIN token.
Enlivex's shares, ticker symbol ENLV, were down about 5%, at $1.05 per share, in early trading on Tuesday, according to Yahoo Finance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs Identifies Key Trend Lines; Nasdaq's Last Line of Defense Is in Jeopardy
The Nasdaq 100 Index has declined for four consecutive weeks and is currently testing a key trend line connecting the 2025 and 2026 lows at 26,630 points. Despite strong third-quarter earnings, heightened risk aversion and surging panic indicators have led investors to factor in potential slowdown expectations for 2028, causing stock prices to continue falling. With significant outflows of foreign capital and sharp valuation divergences, the market is awaiting the test of this week's CPI data and chip giant earnings reports.

Goldman Sachs backs Oracle (ORCL.US): AI financing concerns may be exaggerated; risks of ongoing projects are controllable
Goldman Sachs maintains a "Buy" rating for Oracle with a 12-month target price of $206.

Why Are Bitcoin and US Stock Market Falling? Will the Sell-Off Continue This Week?
Midterm elections expose market vulnerability! AI trading faces rigorous scrutiny, U.S. stock earnings expectations may undergo major adjustments
The results of the US midterm elections and the subsequent market crash have exposed the vulnerability caused by the market’s excessive concentration of bets on artificial intelligence (AI). Investors may need to readjust their expectations for investment returns.

